Abstract
Background Genetic susceptibility to inflammatory bowel disease (IBD) has been widely studied, whereas the genetic contribution to disease progression over time remains largely unknown. In a unique population-based cohort, we explored if genetic susceptibility to IBD associated with disease course severity.
Methods In a Danish nationwide cohort of 3688 patients with Crohn’s disease (CD), 4491 patients with ulcerative colitis (UC), and 9469 controls, we estimated polygenic scores (PGS) for IBD susceptibility. We then investigated the association between susceptibility PGS and severe versus less severe disease courses. Patients were categorized as having a severe disease course if needing I) at least two IBD-related hospitalizations exceeding two days, II) at least two IBD-related major surgeries, III) one hospitalization and one major surgery not overlapping in time, or IV) total use of minimum 5000 mg systemic corticosteroids within the first three years of diagnosis. Secondary analyses explored the association with other severity measures including inflammatory markers, exposure to biologics and immunomodulators, and time to hospitalization and major IBD-related surgery. Statistical analyses included logistic, linear, and Cox proportional hazards regression, and predictive modeling using random forest.
Findings Patients with severe disease courses had higher susceptibility PGS than patients with less severe disease courses (CD: OR=1·27, P=7·73×10−10, UC: OR=1·35, P=7·29×10−17 per SD increase in susceptibility PGS). When comparing the highest versus lowest PGS quintile, we observed a hazard ratio (HR) for major surgery of 2·74 (P=7·19×10−18) in patients with CD and 2·04 (P=4·36×10−7) in patients with UC. A higher susceptibility PGS was also associated with longer and more frequent hospitalizations, higher levels of C-reactive protein, decreased hemoglobin, and a higher need for corticosteroids, immunomodulators, and biologic therapies.
Interpretation Patients with a higher genetic burden for developing IBD also experience a more severe disease course, suggesting a shared genetic architecture between disease susceptibility and severity.
Funding Danish National Research Foundation, DNRF148, Lundbeck Foundation, R313-2019-857, Novo Nordisk Foundation, NNF23OC0087616, Danish Colitis Crohn Association.
Competing Interest Statement
TJ reports consultancy for Ferring and Pfizer. LL reports speaker fee from Takeda and advisory board for Tillotts. HAJ reports speaker fee for Tillotts. The remaining authors have no disclosures.
Funding Statement
Danish National Research Foundation, DNRF148, Lundbeck Foundation, R313-2019-857, Novo Nordisk Foundation, NNF23OC0087616, Danish Colitis Crohn Association.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The PREDICT-NBS cohort was approved by the Research Ethical Committee of the Capital Region of Denmark (H-20048987) and no direct consent was required. The NorDIBD cohort was approved by the Research Ethical Committee of the North Denmark Region (N-20170005-N-20200071). Oral and written consents were obtained, and we followed up on whether any participant withdrew their consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data sharing statement
This work uses data from the Danish National Health registries (https://sundhedsdatastyrelsen.dk), which is protected by the Danish Act on Processing of Personal Data. To access the data an application is required, which must be approved from the Danish Data Protection Agency and the Danish Health Data Authority. Handling of the data must be carried out by a Danish institution.
